Риски прогрессирования цереброваскулярной патологии, связанные с активностью пуринергической системы мозга

Закрыть метаданные

До настоящего времени отсутствует понимание связи факторов риска и механизмов прогрессирования цереброваскулярной патологии. В обзоре представлены факты, подтверждающие участие разных подтипов пуриновых Р2-рецепторов в модуляции активности нейронов, росте и миелинизации отростков, миграции и фагоцитозе микроглии, астроглиозе, регуляции тонуса сосудов, тромбозе и ангиогенезе, нейровоспалении и иммунных реакциях. Приведенные данные позволяют рассматривать возможность активации пуринергической системы мозга при действии основных факторов риска развития цереброваскулярной патологии (возраст, артериальная гипертензия, сахарный диабет) как стереотипный механизм, способный влиять на гомеостаз ансамбля «нейрон—глия—капилляр». Пуринергические Р2-рецепторы могут быть потенциальной мишенью для разработки фармакологических методов ограничения прогрессирования цереброваскулярной патологии.

Ключевые слова:

цереброваскулярная патология

факторы риска

пуринергическая система мозга

Авторы:

Баринов Э.Ф.

ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»

Статинова Е.А.

ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»

Сохина В.С.

ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»

Фабер Т.И.

ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»

Даты поступления:

22.01.2020

Даты принятия в печать:

23.01.2020

Список литературы:

Rizzoni D, Rizzoni M, Nardin M, Chiarini G, Agabiti-Rosei C, Aggiusti C, Paini A, Salvetti M, Muiesan ML. Vascular Aging and Disease of the Small Vessels. High Blood Press Cardiovasc Prev. 2019;26(3):183-189. https://doi.org/10.1007/s40292-019-00320-w
Kern KC, Liebeskind DS. Vessel Wall Imaging of Cerebrovascular Disorders. Curr Treat Options Cardiovasc Med. 2019;21(11):65. https://doi.org/10.1007/s11936-019-0782-8
Aguilar-Salinas P, Agnoletto GJ, Brasiliense LBC, Santos R, Granja MF, Gonsales D, Aghaebrahim A, Sauvageau E, Hanel RA. Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study. J Neurointerv Surg. 2019;11(4):347-351. https://doi.org/10.1136/neurintsurg-2018-014396
Arboix A, Massons J, García-Eroles L, Targa C, Comes E, Parra A. Clinical predictors of lacunar syndrome not due to lacunar infarction. BMC Neurol. 2010;10:31. https://doi.org/10.1186/1471-2377-10-31
Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76(10):2289-2304. https://doi.org/10.1253/circj.cj-12-1036
Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535(7613):551-555. https://doi.org/10.1038/nature18928
Yang Q, Guo M, Wang X, Zhao Y, Zhao Q, Ding H, Dong Q, Cui M. Ischemic preconditioning with a ketogenic diet improves brain ischemic tolerance through increased extracellular adenosine levels and hypoxia-inducible factors. Brain Res. 2017;1667:11-18. https://doi.org/10.1016/j.brainres.2017.04.010
Weisman GA, Ajit D, Garrad R, Peterson TS, Woods LT, Thebeau C, Camden JM, Erb L. Neuroprotective roles of the P2Y(2) receptor. Purinergic Signal. 2012;8(3):559-578. https://doi.org/10.1007/s11302-012-9307-6
von Kügelgen I. Pharmacology of P2Y receptors. Brain Res Bull. 2019;151:12-24. https://doi.org/10.1016/j.brainresbull.2019.03.010
Volonté C, Amadio S, Cavaliere F, D’Ambrosi N, Vacca F, Bernardi G. Extracellular ATP and neurodegeneration. Curr Drug Targets CNS Neurol Disord. 2003;2(6):403-412. https://doi.org/10.1016/j.pharmthera.2005.06.002
Franke H, Illes P. Nucleotide signaling in astrogliosis. Neurosci Lett. 2014;565:14-22. https://doi.org/10.1016/j.neulet.2013.09.056
Boué-Grabot E, Pankratov Y. Modulation of Central Synapses by Astrocyte-Released ATP and Postsynaptic P2X Receptors. Neural Plast. 2017;9454275. https://doi.org/10.1155/2017/9454275
Beckel JM, Gómez NM, Lu W, Campagno KE, Nabet B, Albalawi F, Lim JC, Boesze-Battaglia K, Mitchell CH. Stimulation of TLR3 triggers release of lysosomal ATP in astrocytes and epithelial cells that requires TRPML1 channels. Sci Rep. 2018;8(1):5726. https://doi.org/10.1038/s41598-018-23877-3
Franke H, Illes P. Involvement of P2 receptors in the growth and survival of neurons in the CNS. Pharmacol Ther. 2006;109(3):297-324. https://doi.org/10.1016/j.pharmthera.2005.06.002
Simões AP, Silva CG, Marques JM, Pochmann D, Porciúncula LO, Ferreira S, Oses JP, Beleza RO, Real JI, Köfalvi A, Bahr BA, Lerma J, Cunha RA, Rodrigues RJ. Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation. Cell Death Dis. 2018;9(3):297. https://doi.org/10.1038/s41419-018-0351-1
Förster D, Reiser G. Supportive or detrimental roles of P2Y receptors in brain pathology? The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies. Purinergic Signal. 2015;11(4):441-454. https://doi.org/10.1007/s11302-015-9471-6
Zhou KQ, Green CR, Bennet L, Gunn AJ, Davidson JO.The Role of Connexin and Pannexin Channels in Perinatal Brain Injury and Inflammation. Front Physiol. 2019;10:141. https://doi.org/10.3389/fphys.2019.00141
Pedata F, Dettori I, Coppi E, Melani A, Fusco I, Corradetti R, Pugliese AM. Purinergic signalling in brain ischemia. Neuropharmacology. 2016;104:105-130. https://doi.org/10.1016/j.neuropharm.2015.11.007
Weisman GA, Camden JM, Peterson TS, Ajit D, Woods LT, Erb L. P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y₂ receptor interactions in neuroinflammation. Mol Neurobiol. 2012;46(1):96-113. https://doi.org/10.1007/s12035-012-8263-z
Kylhammar D, Bune LT, Rådegran G.P2Y₁ and P2Y₁₂ receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig. Eur J Appl Physiol. 2014;114(9):1995-2006. https://doi.org/10.1007/s00421-014-2921-y
Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol. 2017;8:661. https://doi.org/10.3389/fphar.2017.00661
Nishimura A, Sunggip C, Tozaki-Saitoh H, Shimauchi T, Numaga-Tomita T, Hirano K, Ide T, Boeynaems JM, Kurose H, Tsuda M, Robaye B, Inoue K, Nishida M.Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension. Sci Signal. 2016;9(411):ra7. https://doi.org/10.1126/scisignal.aac9187
Nishimura A, Sunggip C, Oda S, Numaga-Tomita T, Tsuda M, Nishida M. Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases. Pharmacol Ther. 2017;180:113-128. https://doi.org/10.1016/j.pharmthera.2017.06.010
von Kügelgen I, Hoffmann K. Pharmacology and structure of P2Y receptors. Neuropharmacology. 2016;104:50-61. https://doi.org/10.1016/j.neuropharm.2015.10.030
Mo M, Eyo UB, Xie M, Peng J, Bosco DB, Umpierre AD, Zhu X, Tian DS, Xu P, Wu LJ. Microglial P2Y12 Receptor Regulates Seizure-Induced Neurogenesis and Immature Neuronal Projections. J Neurosci. 2019;20:39(47):9453-9464. https://doi.org/10.1523/jneurosci.0487-19.2019
Zhao B, Zhao CZ, Zhang XY, Huang XQ, Shi WZ, Fang SH, Lu YB, Zhang WP, Xia Q, Wei EQ. The new P2Y-like receptor G protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats. Neuroscience. 2012;202:42-57. https://doi.org/10.1016/j.neuroscience.2011.11.066
Fumagalli M, Lecca D, Abbracchio MP. CNS remyelination as a novel eparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17. Neuropharmacology. 2016;104:82-93. https://doi.org/10.1016/j.neuropharm.2015.10.005
Ribeiro DE, Glaser T, Oliveira-Giacomelli Á, Ulrich H. Purinergic receptors in neurogenic processes. Brain Res Bull. 2019;151:3-11. https://doi.org/10.1016/j.brainresbull.2018.12.013
Sousa JB, Diniz C.The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges. Molecules. 2017;22(5). pii: E752. https://doi.org/10.3390/molecules22050752
Nathan JR, Lakshmanan G, Michael FM, Seppan P, Ragunathan M. Expression of adenosine receptors and vegf during angiogenesis and its inhibition by pentoxifylline-A study using zebrafish model. Biomed Pharmacother. 2016;84:1406-1418. https://doi.org/10.1016/j.biopha.2016.10.045
Khayat MT, Nayeem MA. The Role of Adenosine A2A Receptor, CYP450s, and PPARs in the Regulation of Vascular Tone. Biomed Res Int. 2017;2017:1720920. https://doi.org/10.1155/2017/1720920
Leiva A, Contreras-Duarte S, Amigo L, Sepúlveda E, Boric M, Quiñones V, Busso D, Rigotti A. Gugulipid causes hypercholesterolemia leading to endothelial dysfunction, increased atherosclerosis, and premature death by ischemic heart disease in male mice. PLoS One. 2017;12(9):e0184280. https://doi.org/10.1371/journal.pone.0184280
Schmidl D, Weigert G, Dorner GT, Resch H, Kolodjaschna J, Wolzt M, Garhofer G, Schmetterer L.Role of adenosine in the control of choroidal blood flow during changes in ocular perfusion pressure. Invest Ophthalmol Vis Sci. 2011;52(8):6035-6039. https://doi.org/10.1167/iovs.11-7491
Geldenhuys WJ, Hanif A, Yun J, Nayeem MA. Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases. Molecules. 2017;22(6). pii: E917. https://doi.org/10.3390/molecules22060917
Arsyad A, Dobson GP. Lidocaine relaxation in isolated rat aortic rings is enhanced by endothelial removal: possible role of Kv, KATP channels and A2a receptor crosstalk. BMC Anesthesiol. 2016;16(1):121. https://doi.org/10.1186/s12871-016-0286-y
Miras-Portugal MT, Queipo MJ, Gil-Redondo JC, Ortega F, Gómez-Villafuertes R, Gualix J, Delicado EG, Pérez-Sen R. P2 receptor interaction and signalling cascades in neuroprotection. Brain Res Bull. 2019;151:74-83. https://doi.org/10.1016/j.brainresbull.2018.12.012
Fan Y, Xie L, Chung CY. Signaling Pathways Controlling Microglia Chemotaxis. Mol Cells. 2017;40(3):163-168. https://doi.org/10.14348/molcells.2017.0011
Jin X, Yamashita T. Microglia in central nervous system repair after injury. J Biochem. 2016;159(5):491-496. https://doi.org/10.1093/jb/mvw009
Calovi S, Mut-Arbona P, Sperlágh B. Microglia and the Purinergic Signaling System. Neuroscience. 2019;405:137-147. https://doi.org/10.1016/j.neuroscience.2018.12.021
Liu PW, Yue MX, Zhou R, Niu J, Huang DJ, Xu T, Luo P, Liu XH, Zeng JW. P2Y12 and P2Y13 receptors involved in ADPβs induced the release of IL-1β, IL-6 and TNF-α from cultured dorsal horn microglia. J Pain Res. 2017;10:1755-1767. https://doi.org/10.2147/jpr.s137131
Swiatkowski P, Murugan M, Eyo UB, Wang Y, Rangaraju S, Oh SB, Wu LJ. Activation of microglial P2Y12 receptor is required for outward potassium currents in response to neuronal injury. Neuroscience. 2016;318:22-33. https://doi.org/10.1016/j.neuroscience.2016.01.008
Kyrargyri V, Madry C, Rifat A, Arancibia-Carcamo IL, Jones SP, Chan VTT, Xu Y, Robaye B, Attwell D. P2Y13 receptors regulate microglial morphology, surveillance, and resting levels of interleukin 1β release. Glia. 2020 Feb;68(2):328-344 https://doi.org/10.1002/glia.23719
Madry C, Kyrargyri V, Arancibia-Cárcamo IL, Jolivet R, Kohsaka S, Bryan RM, Attwell D. Microglial Ramification, Surveillance, and Interleukin-1β Release Are Regulated by the Two-Pore Domain K+ Channel THIK-1. Neuron. 2018;97(2):299-312.e6. https://doi.org/10.1016/j.neuron.2017.12.002
Eyo UB, Peng J, Swiatkowski P, Mukherjee A, Bispo A, Wu LJ. Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J Neurosci. 2014;34(32):10528-10540. https://doi.org/10.1523/jneurosci.0416-14.2014
Xu Y, Hu W, Liu Y, Xu P, Li Z, Wu R, Shi X, Tang Y.P2Y6 Receptor-Mediated Microglial Phagocytosis in Radiation-Induced Brain Injury. Mol Neurobiol. 2016;53(6):3552-3564. https://doi.org/10.1007/s12035-015-9282-3
Suzuki T, Kohyama K, Moriyama K, Ozaki M, Hasegawa S, Ueno T, Saitoe M, Morio T, Hayashi M, Sakuma H. Extracellular ADP augments microglial inflammasome and NF-κB activation via the P2Y12 receptor. Eur J Immunol. 2020 Feb;50(2):205-219 https://doi.org/10.1002/eji.201848013/v4/response1
Reichenbach N, Delekate A, Breithausen B, Keppler K, Poll S, Schulte T, Peter J, Plescher M, Hansen JN, Blank N, Keller A, Fuhrmann M, Henneberger C, Halle A, Petzold GC. P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer’s disease model. J Exp Med. 2018;215(6):1649-1663. https://doi.org/10.1084/jem.20171487
Ye XC, Hu JX, Li L, Li Q, Tang FL, Lin S, Sun D, Sun XD, Cui GY, Mei L, Xiong WC. Astrocytic Lrp4 (Low-Density Lipoprotein Receptor-Related Protein 4) Contributes to Ischemia-Induced Brain Injury by Regulating ATP Release and Adenosine-A2AR (Adenosine A2A Receptor) Signaling. Stroke. 2018;49(1):165-174. https://doi.org/10.1161/strokeaha.117.018115
Quintas C, Vale N, Gonçalves J, Queiroz G. Microglia P2Y13 Receptors Prevent Astrocyte Proliferation Mediated by P2Y1 Receptors. Front Pharmacol. 2018;9:418. https://doi.org/10.3389/fphar.2018.00418

Закрыть метаданные